Datopotamab deruxtecan extends PFS vs chemo for HR+/HER2- breast cancer

Share :
Published: 23 Oct 2023
Views: 145
Dr Aditya Bardia - Mass General Cancer Center, Boston, USA

Dr Bardia talks to ecancer about data he presented at ESMO 2023.

The randomised phase III TROPION-Breast01 trial investigated the effectiveness of datopotamab deruxtecan, an antibody-drug conjugate, compared to chemotherapy in patients with advanced HR+ / HER2 low or negative breast cancer.

The study included 732 patients and found that datopotamab deruxtecan improved progression-free survival compared to chemotherapy.

Overall survival data were not yet mature, but there was a trend favouring the conjugate, and patients on datopotamab deruxtecan experienced fewer severe side effects and dose reductions.

He notes that these results support datopotamab deruxtecan as a promising treatment option for patients with advanced HR+/HER2- breast cancer who have received 1-2 prior lines of chemotherapy. The study is ongoing to assess final overall survival outcomes.